吉瑞治疗
GYRE
6.08
-0.32
-5.00%
吉瑞治疗
US · GYRE
#3470 按市值排名
上市于 2006
6.08
-0.32
-5.00%
实时 - 追踪5344个代码 - 心跳于383秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 68.57% -0.01pp
- 机构数量
- 76 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Public Company60.61%
Individual/Insider5.74%
VC/PE Fund3.54%
Mutual Fund3.43%
Hedge Fund0.93%
Other25.69%
主要股东 截至 2026-03-31
GNI Group Ltd.
60.36% · 64.01M 股
HongShan Capital Advisors Limited
3.54% · 3.75M 股
Songjiang Ma
2.65% · 2.81M 股
Ying Luo
2.42% · 2.57M 股
Vanguard Capital Management, LLC
0.97% · 1.03M 股
BlackRock
0.94% · 993.94K 股
Octagon Capital Advisors LP
0.90% · 954.42K 股
Weiguo Ye
0.66% · 700.00K 股
Geode Capital Management, LLC
0.50% · 532.95K 股
State Street Global Advisors
0.23% · 245.40K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 23次买入 · 24次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| GNI Group Ltd. | -- | 60.36% |
| Songjiang Ma | President & Board Member | 2.65% |
| Ying Luo | Chairperson | 2.42% |
| Weiguo Ye | Chief Operating Officer | 0.66% |
| Thomas Eastling | Director | 0.01% |
| Dan Weng | Director | -- |
| David M. Epstein | Director | -- |
| Ping Zhang | Lead Independent Director | -- |
| Renate Parry | Board Member | -- |
| Gordon Carmichael | Board Member | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-06-17 | Weiguo Ye | Chief Operating Officer | Derivative Exercise and Sale | -11,000 | $0.75–6.35 |
| 2026-06-10 | Weiguo Ye | Chief Operating Officer | Derivative Exercise and Sale | -2,800 | $0.75–6.17 |
| 2026-06-09 | Dan Weng | Director | Other Derivative Acquisition | +40,000 | $5.95 |
| 2026-06-09 | David M. Epstein | Director | Other Derivative Acquisition | +40,000 | $5.95 |
| 2026-06-09 | Ping Zhang | Lead Independent Director | Other Derivative Acquisition | +40,000 | $5.95 |
| 2026-06-09 | Renate Parry | Board Member | Other Derivative Acquisition | +40,000 | $5.95 |
| 2026-06-09 | Gordon Carmichael | Board Member | Other Derivative Acquisition | +40,000 | $5.95 |
| 2026-06-09 | Weiguo Ye | Chief Operating Officer | Derivative Exercise and Sale | -20,918 | $0.75–6.21 |
| 2026-06-09 | Rodney Nussbaum | Director | Other Derivative Acquisition | +40,000 | $5.95 |
| 2026-06-07 | Ying Luo | Chairperson | Other Derivative Acquisition | +120,000 | $6.05 |
| 2026-06-07 | Joshua Bergmann | General Counsel | Other Derivative Acquisition | +50,000 | $6.05 |
| 2026-06-04 | Weiguo Ye | Chief Operating Officer | Derivative Exercise and Sale | -34,976 | $0.75–6.40 |
| 2026-05-25 | Weiguo Ye | Chief Operating Officer | Derivative Exercise and Sale | -7,500 | $0.75–6.10 |
| 2026-05-20 | Weiguo Ye | Chief Operating Officer | Derivative Exercise and Sale | -22,220 | $0.75–6.15 |
| 2026-05-18 | Weiguo Ye | Chief Operating Officer | Derivative Exercise and Sale | -9,320 | $0.75–6.62 |
| 2026-05-14 | Weiguo Ye | Chief Operating Officer | Derivative Exercise and Sale | -28,680 | $0.75–6.91 |
| 2026-05-13 | Ping Zhang | Lead Independent Director | Derivative Sale to Issuer | -250,000 | -- |
| 2026-05-12 | Weiguo Ye | Chief Operating Officer | Intent to Sell (Form 144) | -300,000 | $7.07 |
| 2026-05-05 | Ying Luo | Chairperson | Automatic Disposition | -10,315 | $8.01–8.04 |
| 2026-05-03 | Thomas Eastling | Director | Other Derivative Acquisition | +408,757 | $0.32–5.98 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
吉瑞治疗 讨论区 0 条评论